|
1
|
Karapetis CS, Khambata-Ford S, Jonker DJ,
O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD,
Robitaille S, et al: K-ras Mutations and benefit from cetuximab in
advanced colorectal cancer. N Engl J Med. 359:1757–1765.
2008.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Amado RG, Wolf M, Peeters M, Van Cutsem E,
Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, et
al: Wild-type KRAS is required for panitumumab efficacy in patients
with metastatic colorectal cancer. J Clin Oncol. 26:1626–1634.
2008.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Imamura Y, Lochhead P, Yamauchi M, Kuchiba
A, Qian ZR, Liao X, Nishihara R, Jung S, Wu K, Nosho K, et al:
Analyses of clinicopathological, molecular, and prognostic
associations of KRAS codon 61 and codon 146 mutations in colorectal
cancer: Cohort study and literature review. Mol Cancer.
13(135)2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Lièvre A, Bachet JB, Le Corre D, Boige V,
Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, et al:
KRAS mutation status is predictive of response to cetuximab therapy
in colorectal cancer. Cancer Res. 66:3992–3995. 2006.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Dahabreh IJ, Terasawa T, Castaldi PJ and
Trikalinos TA: Systematic review: Anti-epidermal growth factor
receptor treatment effect modification by KRAS mutations in
advanced colorectal cancer. Ann Intern Med. 154:37–49.
2011.PubMed/NCBI View Article : Google Scholar
|
|
6
|
De Roock W, Jonker DJ, Di Nicolantonio F,
Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M,
Piessevaux H, et al: Association of KRAS p.G13D mutation with
outcome in patients with chemotherapy-refractory metastatic
colorectal cancer treated with cetuximab. JAMA. 304:1812–1820.
2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kumar SS, Price TJ, Mohyieldin O, Borg M,
Townsend A and Hardingham JE: KRAS G13D mutation and sensitivity to
cetuximab or panitumumab in a colorectal cancer cell line model.
Gastrointest Cancer Res. 7:23–26. 2014.PubMed/NCBI
|
|
8
|
Kitazawa M, Hida S, Fujii C, Taniguchi S,
Ito K, Matsumura T, Okada N, Sakaizawa T, Kobayashi A, Takeoka M
and Miyagawa SI: ASC induces apoptosis via activation of caspase-9
by enhancing Gap junction-mediated intercellular communication.
PLoS One. 12(e0169340)2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Koyama M, Kitazawa M, Nakamura S,
Matsumura T, Miyazaki S, Miyagawa Y, Muranaka F, Tokumaru S,
Okumura M, Yamamoto Y, et al: Low-dose trametinib and Bcl-xl
antagonist have a specific antitumor effect in KRAS-mutated
colorectal cancer cells. Int J Oncol. 57:1179–1191. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
AACR Project GENIE Consortium. AACR
Project GENIE: Powering precision medicine through an International
Consortium. Cancer Discov. 7:818–831. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Des Guetz G, Schischmanoff O, Nicolas P,
Perret GY, Morere JF and Uzzan B: Does microsatellite instability
predict the efficacy of adjuvant chemotherapy in colorectal cancer?
A systematic review with meta-analysis. Eur J Cancer. 45:1890–1896.
2009.PubMed/NCBI
|
|
12
|
Poulikakos PI, Zhang C, Bollag G, Shokat
KM and Rosen N: RAF inhibitors transactivate RAF dimers and ERK
signalling in cells with wild-type BRAF. Nature. 464:427–430.
2010.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Prahallad A, Sun C, Huang S, Di
Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A
and Bernards R: Unresponsiveness of colon cancer to BRAF(V600E)
inhibition through feedback activation of EGFR. Nature.
483:100–103. 2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Engelman JA, Chen L, Tan X, Crosby K,
Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y,
et al: Effective use of PI3K and MEK inhibitors to treat mutant
Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med.
14:1351–1356. 2008.PubMed/NCBI View
Article : Google Scholar
|
|
15
|
Ebi H, Corcoran RB, Singh A, Chen Z, Song
Y, Lifshits E, Ryan DP, Meyerhardt JA, Benes C, Settleman J, et al:
Receptor tyrosine kinases exert dominant control over PI3K
signaling in human KRAS mutant colorectal cancers. J Clin Invest.
121:4311–4321. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
16
|
Turke AB, Song Y, Costa C, Cook R, Arteaga
CL, Asara JM and Engelman JA: MEK inhibition leads to PI3K/AKT
activation by relieving a negative feedback on ERBB receptors.
Cancer Res. 72:3228–3237. 2012.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Manchado E, Weissmueller S, Morris JP IV,
Chen CC, Wullenkord R, Lujambio A, de Stanchina E, Poirier JT,
Gainor JF, Corcoran RB, et al: A Combinatorial strategy for
treating KRAS-mutant lung cancer. Nature. 534:647–651.
2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Lin L, Sabnis AJ, Chan E, Olivas V, Cade
L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, et al: The Hippo
effector YAP promotes resistance to RAF- and MEK-targeted cancer
therapies. Nat Genet. 47:250–256. 2015.PubMed/NCBI View
Article : Google Scholar
|
|
19
|
Corcoran RB, Cheng KA, Hata AN, Faber AC,
Ebi H, Coffee EM, Greninger P, Brown RD, Godfrey JT, Cohoon TJ, et
al: Synthetic lethal interaction of combined BCL-XL and MEK
inhibition promotes tumor regressions in KRAS mutant cancer models.
Cancer Cell. 23:121–128. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ziemke EK, Dosch JS, Maust JD, Shettigar
A, Sen A, Welling TH, Hardiman KM and Sebolt-Leopold JS:
Sensitivity of KRAS-mutant colorectal cancers to combination
therapy that cotargets MEK and CDK4/6. Clin Cancer Res. 22:405–414.
2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Tao Z, Le Blanc JM, Wang C, Zhan T, Zhuang
H, Wang P, Yuan Z and Lu B: Coadministration of Trametinib and
Palbociclib radiosensitizes KRAS-mutant non-small cell lung cancers
in vitro and in vivo. Clin Cancer Res. 22:122–133. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Lee MS, Helms TL, Feng N, Gay J, Chang QE,
Tian F, Wu JY, Toniatti C, Heffernan TP, Powis G, et al: Efficacy
of the combination of MEK and CDK4/6 inhibitors in vitro and in
vivo in KRAS mutant colorectal cancer models. Oncotarget.
7:39595–39608. 2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Ryan MB, Fece de la Cruz F, Phat S, Myers
DT, Wong E, Shahzade HA, Hong CB and Corcoran RB: Vertical pathway
inhibition overcomes adaptive feedback resistance to KRAS G12C
inhibition. Clin Cancer Res. 26:1633–1643. 2020.PubMed/NCBI View Article : Google Scholar
|
